Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.
Chupradit S, Wamalwa DC, Maleche-Obimbo E, Kekitiinwa AR, Mwanga-Amumpaire J, Bukusi EA, Nyandiko WM, Mbuthia JK, Swanson A; DNDi Clinical Team; Cressey TR, Punyawudho B, Musiime V; LIVING Study Team. Chupradit S, et al. Among authors: cressey tr. Clin Pharmacol Ther. 2024 May;115(5):1105-1113. doi: 10.1002/cpt.3174. Epub 2024 Jan 21. Clin Pharmacol Ther. 2024. PMID: 38247190
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
Cressey TR, Punyawudho B, Le Coeur S, Jourdain G, Saenjum C, Capparelli EV, Jittayanun K, Phanomcheong S, Luvira A, Borkird T, Puangsombat A, Aarons L, Sukrakanchana PO, Urien S, Lallemant M; PHPT-5 study team. Cressey TR, et al. J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):554-560. doi: 10.1097/QAI.0000000000001447. J Acquir Immune Defic Syndr. 2017. PMID: 28489732 Free PMC article. Clinical Trial.
Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV.
Ford D, Turner R, Turkova A, Penazzato M, Musiime V, Bwakura-Dangarembizi M, Violari A, Chabala C, Puthanakit T, Sudjaritruk T, Cressey TR, Lallemant M, Gibb DM. Ford D, et al. Among authors: cressey tr. J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1(1):S40-S48. doi: 10.1097/QAI.0000000000001748. J Acquir Immune Defic Syndr. 2018. PMID: 29994919 Free PMC article.
Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement.
Eke AC, Olagunju A, Momper J, Penazzato M, Abrams EJ, Best BM, Capparelli EV, Bekker A, Belew Y, Kiser JJ, Struble K, Taylor G, Waitt C, Mirochnick M, Cressey TR, Colbers A; participants of the WHO-IMPAACT workshop on “Approaches to Optimize and Accelerate Pharmacokinetic Studies in Pregnant and Lactating Women”. Eke AC, et al. Among authors: cressey tr. Clin Pharmacol Ther. 2021 Jul;110(1):36-48. doi: 10.1002/cpt.2048. Epub 2020 Oct 15. Clin Pharmacol Ther. 2021. PMID: 32930408 Free PMC article.
Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE, Smolders EJ, Jourdain G, Burger DM, Colbers AP, Cressey TR; PANNA Network and iTAP Study Group. Bukkems VE, et al. Among authors: cressey tr. J Clin Pharmacol. 2021 Mar;61(3):388-393. doi: 10.1002/jcph.1746. Epub 2020 Sep 22. J Clin Pharmacol. 2021. PMID: 32960984 Free PMC article.
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY Trial Team. Moore CL, et al. Among authors: cressey tr. BMC Infect Dis. 2021 Jan 4;21(1):5. doi: 10.1186/s12879-020-05672-6. BMC Infect Dis. 2021. PMID: 33446115 Free PMC article. Clinical Trial.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team. Turkova A, et al. Among authors: cressey tr. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793. N Engl J Med. 2021. PMID: 34965338 Free PMC article. Clinical Trial.
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial.
Turner RM, Turkova A, Moore CL, Bamford A, Archary M, Barlow-Mosha LN, Cotton MF, Cressey TR, Kaudha E, Lugemwa A, Lyall H, Mujuru HA, Mulenga V, Musiime V, Rojo P, Tudor-Williams G, Welch SB, Gibb DM, Ford D, White IR; the ODYSSEY Trial Team. Turner RM, et al. Among authors: cressey tr. BMC Med Res Methodol. 2022 Feb 20;22(1):49. doi: 10.1186/s12874-022-01539-3. BMC Med Res Methodol. 2022. PMID: 35184739 Free PMC article.
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, Cotton MF, Lugemwa A, Variava E, Ahimbisibwe GM, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo CM, Archary M, Ferrand RA, Violari A, Gibb DM, Burger DM, Ford D, Colbers A; ODYSSEY Trial Team. Turkova A, et al. Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19. Lancet HIV. 2022. PMID: 35868341 Free PMC article. Clinical Trial.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P, Lugemwa A, Wynne B, Mujuru HA, Violari A, Kityo CM, Archary M, Variava E, White E, Turner RM, Shakeshaft C, Ali S, Nathoo KJ, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa AR, Giaquinto C, Rojo P, Gibb DM, Turkova A, Ford D; ODYSSEY Trial Team. Amuge P, et al. Lancet HIV. 2022 Sep;9(9):e638-e648. doi: 10.1016/S2352-3018(22)00163-1. Lancet HIV. 2022. PMID: 36055295 Free PMC article. Clinical Trial.
159 results